CVS 8-K Current Reports

CVS HEALTH Corp 8-K Report, Executive Changes (Aug 17, 2026)

CVS Health filed an 8-K on August 17, 2026 reporting a board change: director Larry M. Robbins resigned effective August 13, 2026, and the Board appointed Teresa Heitsenrether, JPMorgan Chase's Executive Vice President and Chief Data & Analytics Officer, as a new director effective November 18, 2026. The filing states Robbins's resignation was not due to any disagreement with the company on operations, policies, or practices. Heitsenrether was determined to be independent under NYSE and company governance standards, and her director compensation will mirror that of other non-employee directors, prorated for her start date. No arrangements or related-party transactions tied to her appointment were disclosed. The press release frames the change as part of CVS's transition toward a consumer-focused health technology company, with management emphasizing data, analytics, AI, and operational transformation expertise. Robbins, the CEO of activist investor Glenview, had served on the Board since 2024 and on the Audit and Public Policy and External Affairs Committees. In his departure statement he credited the Board with governance refresh, balance sheet repair, and improved financial performance over the period. For investors, the filing is a governance update rather than a financial disclosure: it contains no earnings, guidance, or capital allocation information. The notable points are the exit of an activist-affiliated director, the addition of an independent director with large-scale financial services and technology experience, and the deferred start date that leaves a roughly three-month gap before Heitsenrether joins.

Aug 17, 2026 8-K

Leadership ChangesShareholder Matters

CVS HEALTH Corp 8-K Report, Financial Results (Aug 5, 2026)

CVS Health reported strong second-quarter 2026 results, with total revenues of $106.1 billion (up 7.3% year-over-year), GAAP diluted EPS of $2.31 (versus $0.80), and Adjusted EPS of $2.58 (versus $1.81). The improvement was driven mainly by the Health Care Benefits segment, where adjusted operating income rose 85.5% to $2.4 billion and the medical benefit ratio improved 250 basis points to 87.4%. The comparison is also flattered by the absence of $833 million in legacy litigation charges and a $471 million Group Medicare Advantage premium deficiency reserve recorded in the prior-year quarter. Consolidated adjusted operating income rose 35.4% to $5.2 billion, with all three operating segments contributing growth. Management raised full-year 2026 guidance: GAAP diluted EPS to $6.84–$7.04 (from $6.24–$6.44), Adjusted EPS to $7.90–$8.10 (from $7.30–$7.50), and cash flow from operations to at least $11.5 billion (from at least $9.5 billion). The raise reflects gains in Health Care Benefits and Pharmacy & Consumer Wellness, while management kept a cautious stance for the rest of the year citing elevated cost trends and possible macro headwinds. Year-to-date operating cash flow was $10.6 billion, and the Health Care Benefits segment's Commercial premium revenue fell 19.7%, reflecting the exit from the individual exchange business. The quarter shows meaningful margin recovery in managed care, while Health Services and Pharmacy & Consumer Wellness delivered steadier, lower-growth earnings. Investors should weigh the strength of the reported improvement against the cautious tone on the back half and the fact that much of the year-over-year gain reflects lapping prior-year charges. Note that the 8-K itself is a furnishing of the earnings release under Item 2.02 and is not deemed filed under the Exchange Act.

Aug 5, 2026 8-K

CVS HEALTH Corp 8-K Report, Executive Changes (May 18, 2026)

CVS Health Corporation (CVS) filed an 8-K report on May 18, 2026, detailing the outcomes of its 2026 Annual Meeting of Stockholders held on May 14, 2026. The primary focus of this filing is the shareholder approval of the new 2026 Incentive Compensation Plan (ICP), which will replace the existing 2017 plan for awards granted after May 14, 2026. This plan was overwhelmingly approved by stockholders, signaling confidence in the company's executive compensation strategy moving forward. In addition to the approval of the 2026 ICP, the filing confirms the re-election of all 13 nominated directors for one-year terms. Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026 and approved, on an advisory basis, the compensation of the company's named executive officers. A single stockholder proposal regarding the reduction of the threshold for stockholder action by written consent was not approved.

May 18, 2026 8-K

CVS HEALTH Corp 8-K Report, Financial Results (May 6, 2026)

CVS Health reported first-quarter 2026 results that were strong on the bottom line and raised its full-year 2026 guidance. Total revenues rose 6.2% year-over-year to $100.4 billion. GAAP diluted EPS was $2.30 (versus $1.41), and Adjusted EPS was $2.57 (versus $2.25). Operating income increased 38.7% to $4.68 billion, though the prior-year period included a $387 million legacy litigation charge and a $247 million Accountable Care loss that flatter the comparison. Adjusted operating income grew 12.5% to $5.15 billion, driven mainly by the Health Care Benefits segment. The Health Care Benefits segment was the main driver. Its medical benefit ratio improved 270 basis points to 84.6%, reflecting better Government business performance and the absence of a prior-year $448 million premium deficiency reserve tied to the individual exchange business. Adjusted operating income there rose 52.6% to $3.04 billion. Offsetting this, Health Services adjusted operating income fell 7.1% and Pharmacy & Consumer Wellness fell 8.8%, both pressured by pharmacy reimbursement and client price improvements. Operating cash flow was $4.2 billion, slightly below the prior year's $4.6 billion. Management raised 2026 guidance: GAAP diluted EPS to $6.24–$6.44 (from $5.94–$6.14), Adjusted EPS to $7.30–$7.50 (from $7.00–$7.20), and operating cash flow to at least $9.5 billion (from at least $9.0 billion). Management described its outlook for the rest of the year as cautious, citing elevated medical cost trends and potential macro headwinds. This filing is an 8-K furnishing the earnings press release under Item 2.02, so the financial results are not deemed filed for Exchange Act purposes.

May 6, 2026 8-K

Leadership Changes

CVS HEALTH Corp 8-K Report, Executive Changes (Mar 19, 2026)

CVS Health Corporation (CVS) announced a significant addition to its Board of Directors with the election of John E. Gallina, effective March 19, 2026. Mr. Gallina brings extensive financial expertise, having served as the former Executive Vice President and Chief Financial Officer of Elevance Health, Inc. (ELV) for over seven years. His nearly three-decade tenure at Elevance, coupled with prior experience in senior audit and accounting roles, positions him as a valuable asset to CVS Health's governance. Importantly for investors, Mr. Gallina has been appointed to the Board's Audit Committee and has been designated an "audit committee financial expert." This appointment underscores CVS Health's commitment to robust financial oversight and compliance. His compensation as a non-employee director will align with the company's existing practices for its independent board members.

Mar 19, 2026 8-K

CVS HEALTH Corp 8-K Report, Financial Results (Feb 10, 2026)

CVS Health reported fourth-quarter and full-year 2025 results on February 10, 2026, with total revenues reaching a record $402.1 billion for the year, up 7.8%, and fourth-quarter revenues of $105.7 billion, up 8.2%. Full-year GAAP diluted EPS fell to $1.39 from $3.66 in 2024, driven largely by a $5.7 billion goodwill impairment on the Health Care Delivery reporting unit and roughly $1.2 billion of legacy litigation charges. Adjusted EPS rose to $6.75 from $5.42, and adjusted operating income grew 20.6% to $14.4 billion, led by a sharp recovery in the Health Care Benefits segment, where adjusted operating income improved by $2.6 billion on better underlying Government business performance and favorable prior-year reserve development. Fourth-quarter GAAP diluted EPS was $2.30, but this was inflated by a roughly $1.9 billion tax benefit from a worthless stock deduction tied to a subsidiary's 2025 bankruptcy, which is excluded from Adjusted EPS. Adjusted EPS of $1.09 declined from $1.19 a year earlier, as Health Care Benefits posted an adjusted operating loss of $676 million, reflecting Medicare Part D seasonality changes under the Inflation Reduction Act and unfavorable premium deficiency reserves. Medical membership fell to 26.6 million, down 504,000 year over year, with declines in individual exchange and Government lines. Management reaffirmed 2026 guidance of GAAP diluted EPS of $5.94 to $6.14 and Adjusted EPS of $7.00 to $7.20, but lowered its cash flow from operations outlook to at least $9.0 billion from at least $10.0 billion. Full-year operating cash flow was $10.6 billion, and the company returned $3.4 billion in dividends with no share repurchases in 2025. Investors should weigh the strong underlying Government business recovery against the cash flow guidance cut, ongoing pharmacy reimbursement pressure, and the Oak Street clinic closures planned for 2026.

Feb 10, 2026 8-K

CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (Dec 9, 2025)

CVS Health used its December 9, 2025 Investor Day to reset its outlook and set multi-year targets. It raised 2025 guidance modestly across the board: total revenues of at least $400.0 billion (from at least $397.3 billion), adjusted EPS of $6.60 to $6.70 (from $6.55 to $6.65), and adjusted operating income of $14.22 to $14.39 billion (from $14.14 to $14.31 billion). GAAP diluted EPS remains negative at $(0.32) to $(0.22), though that range also improved from prior guidance. Cash flow from operations guidance of $7.5 to $8.0 billion was confirmed. The increases are small, roughly 0.5% to 1% at the midpoint, so the update is more a confirmation of momentum than a major beat. The more important news for investors is 2026 guidance and the multi-year target. CVS initiated 2026 adjusted EPS guidance of $7.00 to $7.20, implying roughly 6% to 9% growth over the 2025 range. It also guided to adjusted operating income of $15.07 to $15.41 billion, GAAP diluted EPS of $5.94 to $6.14, and cash flow from operations of at least $10.0 billion, a sizable step up from 2025. Management committed to a mid-teens adjusted EPS CAGR through 2028, driven by a return to target margins at Aetna, share wins at CVS Caremark, and a path toward breakeven in Health Care Delivery. The company also announced an AI-native, open consumer engagement platform, though the filing gives few financial details on it. The 2025 GAAP results carry large one-time charges, including a $5.725 billion goodwill impairment in Health Care Delivery, $1.22 billion in legacy litigation charges, and a $288 million loss on Accountable Care assets. Management also disclosed a $387 million Omnicare-related False Claims Act charge in Q1 and a $542 million penalty charge in Q2. Together, these explain the negative GAAP EPS against positive adjusted EPS. Investors should weigh the adjusted figures alongside these recurring-looking legacy litigation and impairment items. Also note that Omnicare deconsolidated after its Chapter 11 filing, which produced a $0.38 per share gain that flows through 2025 adjusted results.

Dec 9, 2025 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (Nov 20, 2025)

CVS Health's Board of Directors has appointed President and CEO David Joyner to also serve as Chair of the Board, effective January 1, 2026, as disclosed in an 8-K filed November 20, 2025. The move consolidates the Chair and CEO roles under Joyner, who has led the company since October 2024. The Board explained that it wants one leader with deep industry experience holding both positions, arguing this structure gives the best opportunity to execute the long-term strategy and create stockholder value. The change replaces the current arrangement in which Roger Farah serves as Executive Chair. Farah will remain on the Board, and Michael F. Mahoney will continue as Lead Independent Director, which provides a counterweight to the combined role. The filing discloses no financial results, guidance, or operational metrics, so the announcement is primarily a governance event rather than a financial one. For investors, the key questions are whether a combined Chair/CEO structure with a Lead Independent Director adequately addresses board oversight concerns, and whether Joyner's continued execution on operational and financial improvements justifies greater concentration of authority. The press release points to the company's scale, with roughly 9,000 retail pharmacies, more than 1,000 clinics, an PBM serving about 87 million plan members, and insurance products reaching over 37 million people.

Nov 20, 2025 8-K

CVS HEALTH Corp 8-K Report, Financial Results (Oct 29, 2025)

CVS Health reported third-quarter 2025 results on October 29, 2025, with a headline GAAP loss that was driven almost entirely by a non-cash charge. GAAP diluted loss per share was $3.13, against earnings of $0.07 a year earlier. The result included a $5.7 billion goodwill impairment on the Health Care Delivery reporting unit (Oak Street Health and related clinics) and a $483 million gain on the deconsolidation of Omnicare, which entered Chapter 11 in September. Total revenue rose 7.8% to a record $102.9 billion, and adjusted EPS rose 47% to $1.60 from $1.09. Adjusted operating income increased 35.8% to $3.46 billion, led by a sharp turnaround in Health Care Benefits, where adjusted operating income moved from a $924 million loss to $314 million and the medical benefit ratio improved about 240 basis points to 92.8%. Part of that improvement reflected favorable prior-period reserve development of $1.9 billion year to date and a favorable swing in premium deficiency reserves, so investors should treat some of the margin gain as non-recurring. The company raised its full-year 2025 adjusted EPS guidance to $6.55–$6.65 from $6.30–$6.40 and raised operating cash flow guidance to $7.5–$8.0 billion. It cut GAAP EPS guidance to a loss of $(0.34) to $(0.24) from earnings of $3.84–$3.94, reflecting the goodwill charge and other excluded items. Year-to-date operating cash flow was $7.2 billion, flat year over year, while accounts receivable grew $7.5 billion, and goodwill fell to $85.5 billion. Management also said it plans fewer new primary care clinics in 2026 and beyond and will close certain Oak Street clinics, signaling a retreat from the Health Care Delivery build-out. The Health Services segment is the main drag. Adjusted operating income fell 7.0% on continued client price concessions, and pharmacy claims processed declined 1.8%. Pharmacy & Consumer Wellness adjusted operating income fell 7.4% under reimbursement pressure, even as prescriptions filled rose 6.9%, helped by the Rite Aid prescription file acquisitions. Overall, the quarter shows operational stabilization in the insurance business, but the GAAP results, the Health Care Delivery write-down, and the pressure in PBM and retail pharmacy warrant close attention.

Oct 29, 2025 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (Sep 22, 2025)

CVS Health (NYSE: CVS) disclosed in an 8-K filed September 22, 2025 that its wholly owned indirect subsidiary, Omnicare, LLC, and certain affiliated entities (the "Omnicare Entities") have voluntarily filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Northern District of Texas. The filing is intended to resolve liabilities stemming from a civil lawsuit in the U.S. District Court for the Southern District of New York, in which the court imposed what Omnicare describes as excessive monetary damages for alleged technical violations of pharmacy law. Omnicare also says the process will address broader financial pressures across the long-term care pharmacy industry and let it evaluate restructuring options, including a standalone restructuring or a sale. For investors, the key points are the containment of the financial exposure within a court-supervised process and the operational continuity plan. Omnicare has secured a $110 million debtor-in-possession (DIP) financing agreement with a third party, which it expects, together with operating cash flow and subject to court approval, to provide sufficient liquidity during the case. The company says it intends to keep paying employee wages and benefits and to pay vendors in full under normal terms for post-filing goods and services. The filing does not quantify the district court judgment, Omnicare's liabilities, or the potential impact on CVS's consolidated results, so the financial effect on the parent remains undetermined from this document alone. The filing is largely a disclosure of a major event rather than a financial report, so it contains no revised guidance or audited figures. Investors should watch for first-day court orders, the scope of any claims against the Omnicare Entities, whether the parent provides support or incurs write-downs or deconsolidation effects, and the outcome of the standalone restructuring or sale evaluation. Omnicare's statements characterizing the court's penalty as unconstitutional and the government's knowledge of the practices are the company's own positions and have not been adjudicated in the bankruptcy context.

Sep 22, 2025 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (Aug 15, 2025)

CVS Health Corporation (CVS) has announced the completion of a significant debt offering, raising approximately $3.96 billion in net proceeds. This capital infusion comes from the issuance of four tranches of senior notes with varying maturities and interest rates: $750 million of 5.000% Senior Notes due 2032, $1.5 billion of 5.450% Senior Notes due 2035, $1.25 billion of 6.200% Senior Notes due 2055, and $500 million of 6.250% Senior Notes due 2065. The issuance was conducted under the company's existing shelf registration statement and was facilitated through an Underwriting Agreement with prominent financial institutions. The proceeds are expected to strengthen the company's financial position and provide flexibility for future strategic initiatives or operational needs. Investors should note the mix of long-term debt with coupon rates ranging from 5.000% to 6.250%, reflecting current market conditions for corporate debt.

Aug 15, 2025 8-K

CVS HEALTH Corp 8-K Report, Financial Results (Jul 31, 2025)

CVS Health reported second-quarter 2025 results on July 31, 2025, with total revenues up 8.4% year over year to $98.9 billion, but GAAP diluted EPS fell to $0.80 from $1.41 because of $833 million in legacy litigation charges tied to two court decisions over past business practices (an Omnicare False Claims Act verdict and a PBM reporting case). Adjusted EPS was roughly flat at $1.81 versus $1.83, and adjusted operating income rose 1.7% to $3.81 billion, driven by Health Care Benefits and Pharmacy & Consumer Wellness, partly offset by a 17.8% decline in Health Services. Operating cash flow for the six months was $6.5 billion, down from $8.0 billion a year earlier. Management raised its full-year 2025 Adjusted EPS guidance to $6.30–$6.40 (from $6.00–$6.20) and raised operating cash flow guidance to at least $7.5 billion (from about $7.0 billion), while lowering GAAP diluted EPS guidance to $3.84–$3.94 (from $4.23–$4.43) to reflect the litigation charges. Within Health Care Benefits, the medical benefit ratio rose to 89.9% from 89.6%, pressured by a $471 million premium deficiency reserve in Group Medicare Advantage, while the individual exchange business and prior-period reserve development were favorable. Investors should note that the GAAP-to-adjusted gap remains wide due to roughly $2.0 billion of annual intangible amortization and that the litigation charges are not final, since both matters are subject to appeal and penalty determinations. The announced Rite Aid prescription file and store acquisitions and the new CFO and CMO hires are additional items to monitor. The filing is an 8-K furnishing the earnings press release under Item 2.02 and is not deemed filed for Exchange Act liability purposes.

Jul 31, 2025 8-K

Shareholder Matters

CVS HEALTH Corp 8-K Report, Shareholder Vote Results (May 20, 2025)

CVS Health Corporation (CVS) has filed an 8-K report detailing the results of its Annual Meeting of Stockholders held on May 15, 2025. The meeting confirmed the election of all 13 director nominees for one-year terms, with overwhelming support for each individual candidate. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for 2025. The advisory vote to approve executive compensation was also passed by a majority of shareholders. While the company's proposals received strong backing, a stockholder proposal seeking to reduce the threshold for acting by written consent was not approved. This indicates that the current governance structure and executive compensation practices are largely aligned with shareholder sentiment, reflecting confidence in the current board and leadership. Investors should note the strong shareholder support for the incumbent directors and the ratification of the auditor, which are generally positive indicators for corporate stability and oversight.

May 20, 2025 8-K

CVS HEALTH Corp 8-K Report, Financial Results (May 1, 2025)

CVS Health reported first-quarter 2025 results on May 1, 2025, with total revenues up 7.0% to $94.6 billion, GAAP diluted EPS of $1.41 (up from $0.88), and Adjusted EPS of $2.25 (up from $1.31). The beat was driven mainly by Health Care Benefits, where the medical benefit ratio improved 310 basis points to 87.3%, helped by $1.65 billion of favorable prior-year reserve development and better Medicare performance, including improved Medicare Advantage star ratings for 2025. Adjusted operating income rose 54.9% to $4.6 billion, with gains in all three operating segments. GAAP operating income rose 48.6% to $3.4 billion, but was reduced by a $387 million Omnicare False Claims Act jury verdict charge and a $247 million loss on the wind-down and sale of Accountable Care assets. Management raised its 2025 Adjusted EPS guidance to $6.00-$6.20 (from $5.75-$6.00) and its operating cash flow guidance to about $7.0 billion (from about $6.5 billion). It cut GAAP diluted EPS guidance to $4.23-$4.43 (from $4.58-$4.83), reflecting the Omnicare charge and other non-GAAP items. Management said it remains cautious for the rest of the year because of elevated medical cost trends and possible macro headwinds. The company also announced it will exit the individual ACA exchange business for 2026, and it recorded a $448 million premium deficiency reserve in that line for 2025. For investors, the quarter shows strong underlying Health Care Benefits performance, but much of the upside came from prior-year reserve releases that do not recur, and the GAAP-to-adjusted gap is widening. Investors will likely focus on whether medical cost trends hold, how durable Medicare margins are, and the financial impact of the Omnicare verdict, which the company plans to appeal.

May 1, 2025 8-K

CVS HEALTH Corp 8-K Report, Executive Changes (Apr 8, 2025)

CVS Health announced on April 8, 2025 a planned change in its finance leadership. Brian O. Newman, currently CFO of United Parcel Service and a board member of Colgate-Palmolive, was named Executive Vice President and Chief Financial Officer. He becomes CFO Designate on April 21, 2025 and assumes the CFO role effective May 12, 2025. Thomas F. Cowhey, the incumbent CFO, steps down from that role on the same May 12 date and will remain with the company as Strategic Advisor to CEO David Joyner until an undetermined departure date. For investors, the key items are the orderly handover of the CFO seat, Newman's compensation package (a $1.0 million base salary, a 150% target bonus, and a $7.0 million target annual equity award, with no sign-on award), and an 18-month non-compete and non-solicit covenant. The filing also discloses a second leadership change. Amy L. Compton-Phillips, M.D., formerly chief physician executive at Press Ganey and earlier president and chief clinical officer at Providence Health & Services, becomes Executive Vice President and Chief Medical Officer effective May 19, 2025. She succeeds Sreekanth K. Chaguturu, M.D., who moved to President of Health Care Delivery in November 2024. In a Regulation FD disclosure, CVS said that year-to-date results through February put it on track to meet or exceed its previously issued 2025 full-year guidance. The company cautioned that first-quarter financial closing procedures were not complete, so full-year expectations could still change. Investors should treat the guidance language as preliminary until first-quarter results are released.

Apr 8, 2025 8-K

CVS HEALTH Corp 8-K Report, Financial Results (Feb 12, 2025)

CVS Health reported fourth-quarter and full-year 2024 results that were sharply weaker on profitability even as top-line revenue grew. Total revenues rose 4.2% to $97.7 billion in the quarter and 4.2% to $372.8 billion for the year, but GAAP diluted EPS fell to $1.30 (from $1.58) in Q4 and to $3.66 (from $6.47) for the full year, while Adjusted EPS dropped to $1.19 in Q4 (from $2.12) and to $5.42 for the year (from $8.74). The decline was driven overwhelmingly by the Health Care Benefits segment, which swung to an adjusted operating loss of $439 million in Q4 and posted only $307 million of adjusted operating income for the full year versus $5.6 billion in 2023. The medical benefit ratio rose from 86.2% to 92.5% for the year, reflecting higher utilization, the unfavorable impact of lower Medicare Advantage star ratings for the 2024 payment year, and higher Medicaid acuity. The Health Care Benefits segment also recorded a $885 million favorable prior-year reserve development, which partly cushioned results. Outside of insurance, the Pharmacy & Consumer Wellness segment grew revenue but saw margin pressure, and the Health Services segment saw revenue decline 7.1% on the loss of a large client and continued pricing concessions. Full-year restructuring charges rose to $1.18 billion, including a store impairment tied to planned 2025 store closures, and the company recorded a $100 million opioid litigation charge. Operating cash flow fell to $9.1 billion from $13.4 billion. Management guided 2025 GAAP diluted EPS to $4.58 to $4.83 and Adjusted EPS to $5.75 to $6.00, with operating cash flow of approximately $6.5 billion, implying further earnings pressure relative to 2024 Adjusted EPS. For investors, the key takeaway is that the investment case now hinges on the recovery of Health Care Benefits margins rather than on top-line growth. The 2025 guidance embeds a substantial step-down in cash generation and earnings, so the credibility of management's medical cost trend assumptions, Medicare Advantage star rating recovery, and Medicaid acuity normalization will be central to the stock's trajectory. The quarter also included a $491 million gain on early debt extinguishment, which helped GAAP results but is excluded from Adjusted EPS.

Feb 12, 2025 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (Dec 17, 2024)

On December 16, 2024, CVS Health announced the early results, election of early settlement, and pricing of its cash tender offer (the "Maximum Tender Offer") for a basket of its senior notes and certain Aetna Inc.-issued senior notes. The offer is capped at a Maximum Tender Offer Amount of $1,774,423,242.62 (excluding accrued interest). Holders who tendered by the December 13, 2024 Early Tender Date, which has passed with withdrawal rights expired, will receive the Total Consideration including a $30 per $1,000 Early Tender Payment, plus accrued interest, with settlement expected December 18, 2024. The tender was oversubscribed. Because aggregate purchase prices of notes tendered by the early deadline exceeded the cap, CVS expects to accept the Maximum Tender Offer Amount subject to proration, and no notes tendered after the Early Tender Date are expected to be accepted. Notes in the 2031 (2.125% and 1.875%), 2048 Aetna 4.500%-type series and certain others fell into lower acceptance priority levels, with the 2.125% 2031, 1.875% 2031, 5.050% 2048, 4.500% Aetna 2042 and 1.750% 2030 series receiving 0% proration, meaning those tendered holders will not have notes purchased. The 4.125% 2040 and 2.700% 2040 series were largely accepted, with the 4.125% 2040 series at a 57.5% approximate proration factor. For investors, this filing is primarily a liability management action: CVS is retiring a portion of its outstanding debt through a capped repurchase, with the pricing set by a fixed spread over the relevant Treasury benchmark. The filing does not disclose the funding source or the financial impact on CVS's leverage, earnings, or cash position, and the document itself is a routine tender-offer disclosure with no new operating or guidance information.

Dec 17, 2024 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (Dec 10, 2024)

CVS Health Corporation has announced the successful issuance and sale of a significant amount of junior subordinated notes, totaling $3.0 billion. This includes $2.25 billion in Series A Junior Subordinated Notes due 2055 with a 7.000% fixed-to-fixed rate, and $750 million in Series B Junior Subordinated Notes due 2054 with a 6.750% fixed-to-fixed rate. These notes were offered under the company's existing Form S-3ASR registration statement filed in May 2023. This debt issuance represents a strategic move by CVS Health to bolster its capital structure. The junior subordinated nature of these notes suggests they are intended to enhance the company's financial flexibility, potentially for future investments, acquisitions, or to manage existing debt obligations. Investors should note the specific interest rates and maturity dates, as well as the subordinated status which implies a higher risk profile compared to senior debt but offers a corresponding yield.

Dec 10, 2024 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (Dec 9, 2024)

CVS Health Corporation announced on December 9, 2024 the expiration and preliminary results of its cash tender offers, specifically the 'Any and All' tender offer for its 4.100% Senior Notes due 2025. As of the 5:00 p.m. NYC time expiration on December 6, 2024, holders validly tendered $225,979,000 in principal amount of the $950,087,000 outstanding notes, with an additional $5,000 tendered via guaranteed delivery procedures. CVS expects to accept all validly tendered notes, with settlement expected on December 11, 2024. The filing indicates the transaction is a liability management action, with the purchases to be funded partly from proceeds of newly issued 7.000% Series A Junior Subordinated Notes due 2055 and 6.750% Series B Junior Subordinated Notes due 2054. The filing also references a concurrent Maximum Tender Offer capped at $2.0 billion less the aggregate purchase price of Any and All Notes accepted, meaning the size of that second offer is contingent on the Any and All results and may change as guaranteed-delivery notes settle. The 8-K itself is a routine disclosure under Item 8.01 with the press release furnished as Exhibit 99.1; it does not disclose new earnings, guidance, or operating results. The press release includes a boilerplate note that no recommendation is made to holders regarding tendering. For investors, the key takeaways are the refinancing nature of the transaction, which replaces near-term 2025 maturities with longer-dated junior subordinated debt carrying higher coupons, and the modest scale of the Any and All tender relative to CVS's overall debt structure. Investors should review the Offer to Purchase and the terms of the New Notes for the full economic impact on interest expense and leverage.

Dec 9, 2024 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (Dec 6, 2024)

On December 6, 2024, CVS Health announced the pricing of its cash tender offer for any and all of its outstanding 4.100% Senior Notes due March 25, 2025 (CUSIP 126650CW8). The offer, launched December 2, 2024, covers $950.1 million principal amount outstanding. Holders who validly tender by the 5:00 p.m. ET expiration on December 6 and are accepted for purchase will receive a total consideration of $998.22 per $1,000 principal amount, based on a 4.434% reference yield (the 3.875% UST due March 31, 2025 plus a 25 bps fixed spread), plus accrued and unpaid interest. Settlement is expected December 11, 2024. The filing is a routine liability-management action. Because the notes mature in about three months, the tender effectively retires near-term debt, reducing the company's 2025 maturity wall while using cash on hand or new financing. The 8-K does not disclose the funding source or the total amount of notes that will be tendered. The offer is subject to a financing condition and other general conditions described in the Offer to Purchase, and CVS may amend, extend, or terminate it before expiration. The filing does not indicate a material change to CVS's financial condition or guidance. For investors, the key takeaways are the size of the refinancing effort relative to CVS's debt load and the price paid, which sits just under par. The results of the tender, including the final amount accepted, should be confirmed in a subsequent press release or filing.

Dec 6, 2024 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (Dec 5, 2024)

CVS Health Corporation (CVS) announced on December 3, 2024, that it has entered into an Underwriting Agreement to issue and sell a significant aggregate principal amount of junior subordinated notes. Specifically, the company plans to issue $2.25 billion of 7.000% Series A Junior Subordinated Notes due 2055 and $750 million of 6.750% Series B Junior Subordinated Notes due 2054. This offering is being conducted under the company's existing Shelf Registration Statement filed in May 2023. The anticipated closing date for this transaction is December 10, 2024, subject to customary closing conditions. CVS Health expects to receive net proceeds of approximately $2.96 billion from this offering, after accounting for underwriter discounts and estimated expenses. This capital raise will likely be used to fund general corporate purposes, although the specific use of proceeds is not detailed in this filing. Investors should note that these are junior subordinated notes, which carry a higher risk profile compared to senior debt.

Dec 5, 2024 8-K

Leadership ChangesMaterial AgreementsRegulation FD+1

CVS HEALTH Corp 8-K Report, Corporate Update (Dec 2, 2024)

On December 2, 2024, CVS Health commenced cash tender offers for its own and Aetna's senior notes. The offers cover (1) any and all of the 4.100% Senior Notes due 2025, about $950 million outstanding and maturing March 25, 2025, and (2) up to a $2.0 billion aggregate purchase price of nine other series, with acceptance priority levels set in numerical order. The stated purpose is to retire a portion of CVS's outstanding debt. The company expects to fund the offers with net proceeds from a planned issuance of subordinated debt securities. The timeline has two key dates. Any and All Notes must be tendered by December 6, 2024, with settlement expected December 11. Maximum Tender Offer Notes tendered by the December 13 early tender date receive an early tender payment of $30 per $1,000 principal, and settlement may occur as early as December 18. The final expiration for those notes is December 31, 2024. Pricing is set as a U.S. Treasury yield plus a fixed spread, which ranges from +25 bps on the 2025 notes to +156 bps on the 5.050% 2048 notes. For investors, the main points are a near-term reduction in debt maturities and a shift in the capital structure toward subordinated debt. The offers are not conditioned on a minimum tender amount, but they depend on CVS issuing enough new notes to fund them. If that funding is not raised, CVS may cancel the offers or fund them with cash. The filing is a tender-offer announcement, not an earnings release, and it contains no updated operating or financial results.

Dec 2, 2024 8-K

CVS HEALTH Corp 8-K Report, Material Agreement (Nov 18, 2024)

On November 17-18, 2024, CVS Health entered into a confidentiality agreement with activist investor Glenview Capital Management and, under it, expanded its Board of Directors from 12 to 16 members. Leslie Norwalk, Larry Robbins (Glenview's founder and CEO), Guy Sansone and Doug Shulman were appointed to the Board. The company agreed to nominate all four for election at its 2025 annual meeting and to use reasonable best efforts to secure their election. Norwalk joins the Health Services and Technology Committee, Sansone joins the Audit Committee, and Shulman joins the Management Planning and Development Committee. Glenview and its affiliates are bound by customary standstill restrictions through the thirtieth day before the 2026 director nomination window opens, subject to limited early-termination provisions, along with mutual non-disparagement obligations. The agreement is a governance development with investor-relevant implications. Activist-investor board representation often signals a push for operational and capital allocation changes, and the Glenview press release emphasizes areas such as underwriting discipline, risk management, aligned incentives and optimal capital allocation. Because the company characterized the outcome as a cooperative arrangement, the near-term risk of a proxy contest appears reduced, though the standstill and nomination commitments define the framework for the next two years. The filing does not quantify any financial impact. The filing also discloses executive compensation changes. CEO J. David Joyner, appointed October 17, 2024, has a base salary of $1.5 million, a target bonus of $3.0 million (200% of salary) and a target long-term incentive of $14.5 million. Prem Shah, EVP and Group President, has a base salary of $1.1 million, a target bonus of $1.925 million and a long-term incentive of $9.0 million. Joyner and Shah each received premium-priced stock options with grant-date values of $12 million and $6 million, respectively, and Tilak Mandadi received a $3 million RSU retention award, all with a November 30, 2024 grant date. Norwalk received about $159,170 in 2023 and is owed about $210,120 for 2024 as an expert witness in litigation involving CVS subsidiaries, and the company expects to keep paying her for pending matters. Investors may view this as a potential independence consideration for the board.

Nov 18, 2024 8-K

CVS HEALTH Corp 8-K Report, Executive Changes (Nov 6, 2024)

CVS Health announced two senior leadership appointments on November 6, 2024, disclosed in an 8-K under Items 5.02 and 7.01. Prem S. Shah, age 44 and a company veteran since 2013, was named to the newly created role of Executive Vice President and Group President. He is responsible for operational performance and integrated value creation across CVS Caremark, CVS Pharmacy, and the Health Care Delivery businesses, including Oak Street Health and Signify Health. He previously served as Chief Pharmacy Officer and President of Pharmacy & Consumer Wellness. The filing discloses no family relationships, no related-party transactions under Item 404(a), and no arrangement under which he was appointed. Steven H. Nelson was appointed Executive Vice President and President of Aetna. He most recently served as CEO of ChenMed, a value-based primary care company, and is a former CEO of UnitedHealthcare. Both executives report to CEO David Joyner. The press release frames the moves as strengthening execution and financial performance, and Joyner cited the goal of 'accelerating the plan to advance Aetna forward.' The filing does not disclose compensation terms, financial guidance changes, or a reason for the restructuring. For investors, the key takeaways are a new layer of operational oversight over the retail, pharmacy, and care delivery units, and a fresh leader for Aetna, the managed care segment. The 8-K contains no quantitative financial results, so the market impact will depend on how the company defines the new roles and whether it changes its outlook.

Nov 6, 2024 8-K

Earnings & ResultsLeadership ChangesRegulation FD+1

CVS HEALTH Corp 8-K Report, Financial Results (Nov 6, 2024)

CVS Health reported third-quarter 2024 results that were sharply weaker on profitability even as top-line revenue grew. Total revenues rose 6.3% year over year to $95.4 billion, but GAAP operating income fell 77.5% to $832 million and GAAP diluted EPS dropped to $0.07 from $1.75. Adjusted EPS declined to $1.09 from $2.21, and adjusted operating income fell 42.8% to $2.5 billion. The decline is concentrated in the Health Care Benefits segment, which posted an adjusted operating loss of $924 million and a medical benefit ratio (MBR) of 95.2%, up from 85.7%. Drivers include elevated utilization, roughly $1.1 billion of premium deficiency reserves (PDR) tied to anticipated fourth-quarter losses in Medicare and individual exchange lines, higher Medicaid acuity, and the unfavorable impact of lower Medicare Advantage star ratings for 2024. The quarter also included about $1.2 billion of restructuring charges, including a $607 million store impairment for retail pharmacy closures planned for 2025, which further depressed GAAP results. Partially offsetting the weakness, the Health Services and Pharmacy & Consumer Wellness segments grew adjusted operating income by 17.4% and 14.9%, respectively. Management said the PDR reserves are expected to be substantially released in the fourth quarter of 2024, which would benefit results in that period. Year-to-date operating cash flow was $7.2 billion, down from $16.1 billion a year earlier, and year-to-date share repurchases were $3.0 billion. For investors, the central questions are whether the Health Care Benefits utilization pressure is durable, whether the PDR release materializes as guided, and whether the enterprise restructuring delivers its promised cost savings. The filing itself is the furnishing of an earnings press release under Item 2.02, so the figures are management-reported and not audited for this period.

Nov 6, 2024 8-K

CVS HEALTH Corp 8-K Report, Financial Results (Oct 18, 2024)

CVS Health announced on October 18, 2024 that J. David Joyner, previously EVP and President of Pharmacy Services, has been appointed President and Chief Executive Officer effective October 17, 2024, replacing Karen Lynch, who resigned as CEO and from the Board on the same day. Board Chairman Roger Farah becomes Executive Chairman, and Joyner joins the Board and its Executive Committee. The leadership change was made by the Board, which said it believed it was the right time for a change, and Joyner has 37 years of health care and pharmacy benefit management experience, including prior roles at CVS Caremark. The more consequential news for investors is the preliminary third quarter 2024 update. The company now expects GAAP diluted EPS of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10. Results include roughly $1.1 billion of premium deficiency reserves (PDRs), mainly in the Medicare and Individual Exchange businesses within Health Care Benefits, which reduced Adjusted EPS by $0.63 and are expected to be substantially released in Q4 2024. GAAP results also carry a restructuring charge of about $1.2 billion tied to closing 271 additional retail stores in 2025 and other cost reduction actions. The medical benefit ratio is expected near 95.2%, including a 220-basis-point PDR impact, and management said medical cost trends exceeded its prior outlook. Investors were told not to rely on prior guidance from the August 7, 2024 earnings call. The full Q3 update is scheduled for November 6, 2024. For Ms. Lynch's departure, she is eligible for separation benefits under her employment agreement, and her equity awards no longer face partial-vesting limits, so she can vest in full (performance awards remain subject to performance metrics). She will also serve as an advisor for six months at a monthly fee of $375,000 plus security services, and her non-compete and non-solicit period is extended to 30 months. These terms are notable for governance and cost analysis, though the amounts are modest relative to the company's scale.

Oct 18, 2024 8-K

Leadership ChangesShareholder MattersExhibits & Filings

CVS HEALTH Corp 8-K Report, Financial Results (Aug 7, 2024)

CVS Health reported second-quarter 2024 results on August 7, 2024 that fell well short of prior-year levels in profitability, even as revenue grew. Total revenues rose 2.6% to $91.2 billion, but GAAP diluted EPS declined to $1.41 from $1.48 and Adjusted EPS fell 17% to $1.83 from $2.21. Adjusted operating income dropped 16.4% to $3.74 billion, driven mainly by the Health Care Benefits segment, where the medical benefit ratio (MBR) rose to 89.6% from 86.2% on higher utilization, the unfavorable Medicare Advantage star ratings impact for the 2024 payment year, higher Medicaid acuity, and an exchange risk adjustment change in estimate. Health Care Benefits adjusted operating income fell 39.1% year over year. The more consequential news for investors is the guidance cut. Management lowered full-year 2024 GAAP diluted EPS guidance to $4.95–$5.20 from at least $5.64, Adjusted EPS guidance to $6.40–$6.65 from at least $7.00, and cash flow from operations guidance to approximately $9.0 billion from at least $10.5 billion. The company attributed the revision to continued pressure in Health Care Benefits, partially offset by strong performance in Health Services and Pharmacy & Consumer Wellness. Management also announced immediate leadership changes: Brian Kane is departing, CEO Karen Lynch will directly oversee the Health Care Benefits segment alongside CFO Tom Cowhey, and Katerina Guerraz will serve as segment COO. Offsetting the weakness, Health Services adjusted operating income rose 1.1% despite a 8.8% revenue decline tied to the loss of a large client, and year-to-date operating cash flow was $8.0 billion. The filing's financial statements and the Exhibit 99.1 press release are furnished under Item 2.02 rather than filed, so they are not subject to Section 18 liability. Investors should weigh the sharp earnings reset and the Health Care Benefits turnaround risk against the steadier performance in the pharmacy and services segments.

Aug 7, 2024 8-K

CVS HEALTH Corp 8-K Report, Executive Changes (May 22, 2024)

This 8-K filing from CVS Health reports on the outcomes of its 2024 Annual Meeting of Stockholders held on May 16, 2024. The primary focus for investors is the stockholder approval of amendments to the 2017 Incentive Compensation Plan (ICP), which will increase the number of shares available for issuance by 33.5 million. This action is crucial for the company's ability to continue incentivizing its employees and executives through equity-based compensation in the future. Additionally, the filing confirms the election of all 12 director nominees, the ratification of Ernst & Young LLP as the independent auditor for 2024, and the advisory approval of executive compensation. Conversely, four stockholder proposals concerning worker rights, director re-nomination policies, golden parachutes, and director time commitment disclosures were not approved by the shareholders.

May 22, 2024 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (May 9, 2024)

CVS Health Corporation has announced the issuance and sale of a significant amount of senior notes, totaling $5.5 billion across various maturities. This debt offering includes $1 billion in 5.400% Senior Notes due 2029, $1 billion in 5.550% Senior Notes due 2031, $1.25 billion in 5.700% Senior Notes due 2034, $750 million in 6.000% Senior Notes due 2044, and $1 billion in 6.050% Senior Notes due 2054. This substantial capital raise through long-term debt suggests CVS Health is actively managing its capital structure. Investors should note the various coupon rates and maturity dates, which reflect current market conditions for corporate debt. The issuance was made under the Company's existing Shelf Registration Statement, indicating a pre-established framework for accessing capital markets. While the filing doesn't detail the specific use of proceeds, such debt issuances are often used for general corporate purposes, refinancing existing debt, or funding strategic initiatives.

May 9, 2024 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (May 8, 2024)

CVS Health Corporation (CVS) announced a significant debt offering, raising approximately $4.95 billion through the issuance of senior notes across various maturity dates. The company entered into an Underwriting Agreement on May 7, 2024, to sell $1 billion in 5.400% Senior Notes due 2029, $1 billion in 5.550% Senior Notes due 2031, $1.25 billion in 5.700% Senior Notes due 2034, $750 million in 6.000% Senior Notes due 2044, and $1 billion in 6.050% Senior Notes due 2054. This substantial capital raise, expected to close on May 9, 2024, will provide CVS Health with significant liquidity. Investors should note the varying interest rates and maturity dates, which reflect current market conditions and the company's debt management strategy. The proceeds are intended to strengthen the company's financial position, though the specific use of these funds is not detailed in this filing.

May 8, 2024 8-K

CVS HEALTH Corp 8-K Report, Financial Results (May 1, 2024)

CVS Health reported first-quarter 2024 results on May 1, 2024 that were sharply weaker than the prior year, and it cut its full-year 2024 guidance substantially. Total revenues rose 3.7% to $88.4 billion, but GAAP diluted EPS fell to $0.88 from $1.65 and Adjusted EPS fell to $1.31 from $2.20. Adjusted operating income declined 32.3% to $2.96 billion. The decline was driven mainly by the Health Care Benefits segment, where the medical benefit ratio (MBR) rose to 90.4% from 84.6% on higher Medicare utilization, the impact of lower 2024 Medicare Advantage star ratings, and unfavorable prior-year development. Segment adjusted operating income there fell 59.9%. Management revised 2024 guidance: GAAP diluted EPS to at least $5.64 (from at least $7.06), Adjusted EPS to at least $7.00 (from at least $8.30), and cash flow from operations to at least $10.5 billion (from at least $12.0 billion). The revision assumes the majority of the first-quarter Medicare utilization pressure persists through the rest of 2024. The CEO said the company remains confident in its strategy and has a pathway to address the near-term Medicare Advantage challenges. Other pressures included a 9.7% decline in Health Services revenue after the loss of a large PBM client, and interest expense up 21.6% from debt raised to fund the Signify Health and Oak Street Health acquisitions. Pharmacy & Consumer Wellness was a relative bright spot, with adjusted operating income up 3.8%. For investors, the central question is whether the Medicare Advantage cost pressure is temporary or structural. The guidance cut assumes it persists, so the reset depends on medical cost trends and Medicare Advantage pricing and star-rating recovery. Cash generation also weakened, with operating cash flow of $4.9 billion in the quarter versus $7.4 billion a year earlier.

May 1, 2024 8-K

CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (Mar 5, 2024)

CVS Health Corporation (CVS) filed an 8-K on March 5, 2024, primarily to reaffirm its previously issued full-year 2024 financial guidance. The company's senior management team met with investors and participated in a webcast where they reiterated their commitment to achieving at least $7.06 in GAAP diluted Earnings Per Share (EPS) and at least $8.30 in Adjusted EPS for fiscal year 2024. Additionally, CVS Health confirmed its expectation to generate at least $12.0 billion in cash flow from operations for the same period. During the webcast, the Chief Financial Officer provided updates on recent business trends and initiatives. The filing also includes a reconciliation of projected GAAP diluted EPS to projected Adjusted EPS, detailing adjustments for amortization of intangible assets and acquisition-related integration costs associated with the Signify Health and Oak Street Health acquisitions. Investors should note that the company uses non-GAAP measures to provide a clearer view of underlying business performance and trends.

Mar 5, 2024 8-K

Earnings & ResultsLeadership ChangesRegulation FD+1

CVS HEALTH Corp 8-K Report, Financial Results (Feb 7, 2024)

CVS Health's Q4 and full-year 2023 results, furnished under Item 2.02 with the press release as Exhibit 99.1, show top-line growth alongside margin pressure in its core insurance business. Fourth-quarter revenue rose 11.9% to $93.8 billion and full-year revenue rose 10.9% to $357.8 billion, driven by growth across all segments. Profitability was mixed: full-year GAAP diluted EPS was $6.47 (up from $3.26, which was depressed by prior-year opioid litigation and LTC write-downs), while Adjusted EPS fell to $8.74 from $9.03. Adjusted operating income declined 2.8% for the year, pressured by the Health Care Benefits segment, where the medical benefit ratio rose to 86.2% for the year and 88.5% in the fourth quarter on Medicare Advantage utilization and individual exchange growth. The most consequential item for investors is the guidance cut. Management lowered 2024 GAAP diluted EPS guidance to at least $7.06 from at least $7.26, Adjusted EPS guidance to at least $8.30 from at least $8.50, and cash flow from operations guidance to at least $12.0 billion from at least $12.5 billion. The company attributed the revision to a finalized fourth-quarter medical cost trend analysis and potential elevated medical cost trends in 2024. Cash flow from operations for 2023 was $13.4 billion, down from $16.2 billion in 2022, and the company spent $16.6 billion on acquisitions, including Signify Health and Oak Street Health, which pushed goodwill and intangibles higher and total long-term debt to about $61.4 billion. On the positive side, management announced a 10% increase in the quarterly dividend effective with the February 1, 2024 payment, returned $3.1 billion to shareholders through dividends in 2023, and introduced pricing and reimbursement models (CVS CostVantage and CVS Caremark TrueCost) slated to launch in 2025. The company also renamed its Health Services segment CVS Healthspire. The filing itself is a routine earnings disclosure, but the revised 2024 outlook and rising medical cost pressure are the key items to weigh.

Feb 7, 2024 8-K

CVS HEALTH Corp 8-K Report, Financial Results (Jan 5, 2024)

CVS Health's January 5, 2024 8-K reports leadership changes and reaffirms guidance ahead of a January 8, 2024 investor meeting. Thomas F. Cowhey, who has served as interim CFO since October 13, 2023, was formally appointed Executive Vice President and CFO effective immediately. Shawn M. Guertin, the prior CFO and President of Health Services, is stepping down for family health reasons and will remain on personal leave until his expected departure on May 31, 2024. Mike Pykosz, CEO of Oak Street Health, was formally named President of Health Care Delivery. For investors, the CFO transition is largely a continuity move, since Cowhey has already overseen investor relations, treasury, and finance operations, but the change still introduces some execution and communication risk during a period of integration. The company reaffirmed its full-year 2023 guidance: GAAP diluted EPS of $6.37 to $6.61 and Adjusted EPS of $8.50 to $8.70, with Adjusted EPS now expected in the upper half of the range. Cash flow from operations is expected at the upper end of the $12.5 billion to $13.5 billion range. Full-year 2024 guidance was also reaffirmed at GAAP diluted EPS of at least $7.26, Adjusted EPS of at least $8.50, and operating cash flow of at least $12.5 billion. The company noted that 2023 financial closing procedures are not yet complete, so final results could fall outside the stated ranges. Operationally, management said Medicare Advantage enrollment exceeded expectations during the 2024 annual enrollment period, with a larger-than-historical share of new sales coming from competitor plans. The company expects total MA membership to grow by at least 800,000 in 2024. Separately, a $3.0 billion fixed-dollar accelerated share repurchase became effective January 3, 2024, which supports per-share earnings and signals capital return.

Jan 5, 2024 8-K

CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (Dec 5, 2023)

CVS Health filed this 8-K under Regulation FD in connection with its 2023 Investor Day on December 5, 2023, furnishing Exhibit 99.1 (a press release). The release centers on strategy rather than new financial results: the company introduced CVS CostVantage, a transparent retail pharmacy reimbursement model (launching with commercial PBM clients in 2025), and CVS Caremark TrueCost, a client pricing model with visibility into administrative fees (also planned for 2025). It also rebranded the Health Services segment as CVS Healthspire, which includes Caremark, Cordavis, Oak Street Health, Signify Health, and MinuteClinic. On financials, management reiterated 2023 guidance (adjusted EPS of $8.50 to $8.70, cash flow from operations at the upper end of $12.5 to $13.5 billion) and initiated 2024 projections: adjusted EPS of at least $8.50, adjusted operating income of at least $17.2 billion, and cash flow from operations of at least $12.5 billion. Investors should note that 2024 adjusted EPS guidance at the floor implies roughly flat year-over-year earnings versus the 2023 range, with GAAP diluted EPS of at least $7.26 reflecting lower amortization and non-GAAP adjustments. The company also highlighted Medicare Advantage margin recovery tied to improved Star Ratings beginning in 2025, and announced a quarterly dividend of $0.665 per share, an approximate 10% increase. The filing is largely forward-looking and the Regulation FD disclosure is furnished, not filed, so it does not carry Section 18 liability. Investors should weigh the long-term growth narrative against the near-term earnings outlook, which signals limited growth in 2024 and depends on execution of the 2025 reimbursement model changes.

Dec 5, 2023 8-K

CVS HEALTH Corp 8-K Report, Financial Results (Nov 1, 2023)

CVS Health reported third-quarter 2023 results on November 1, 2023, with total revenues rising 10.6% year over year to $89.8 billion and GAAP diluted EPS of $1.75, compared with a $2.59 loss in the prior-year quarter that was driven by a $5.2 billion opioid litigation charge and a $2.5 billion Omnicare LTC write-down. Adjusted EPS was $2.21, up from $2.17, and adjusted operating income rose 2.5% to $4.46 billion. The headline comparison is flattered by the absence of prior-year charges, so underlying growth is more modest. Adjusted operating income growth came from Health Services, while Health Care Benefits declined 6.4% on higher Medicare Advantage utilization. The Health Care Benefits medical benefit ratio rose 230 basis points to 85.7%, a key pressure point for investors. Management trimmed full-year GAAP diluted EPS guidance to $6.37–$6.61 from $6.53–$6.75, reflecting acquisition-related costs, restructuring, and the LTC loss, while confirming Adjusted EPS guidance of $8.50–$8.70 and operating cash flow guidance of $12.5–$13.5 billion. Interest expense rose 22.4% after debt was raised to fund the Signify Health and Oak Street Health acquisitions, and goodwill and intangibles expanded materially. Year-to-date operating cash flow of $16.1 billion, against $18.1 billion a year earlier, shows the balance sheet and cash generation are under some strain. The filing is a furnished (not filed) Item 2.02 earnings release under Exhibit 99.1. Other notable items include the launch of the Cordavis biosimilar subsidiary, $779 million in quarterly dividends, two new board members, and an Investor Day scheduled for December 5, 2023.

Nov 1, 2023 8-K

CVS HEALTH Corp 8-K Report, Executive Changes (Oct 16, 2023)

CVS Health disclosed on October 16, 2023 that Chief Financial Officer Shawn Guertin has begun a personal leave of absence, effective October 13, 2023, due to unforeseen family medical reasons. The Board appointed Thomas F. Cowhey, Senior Vice President of Corporate Finance, as Interim Chief Financial Officer, effective the same date. Cowhey joined CVS in February 2022, previously served as CFO of Surgery Partners, and has overseen investor relations, corporate development, treasury, and finance operations, which provides continuity in the finance function. The press release also named Oak Street Health CEO Mike Pykosz as interim President of Health Services, a role Guertin also held, indicating a leadership change across two senior positions. Importantly for investors, the Company reaffirmed its full-year 2023 guidance: GAAP diluted EPS of $6.53 to $6.75 and Adjusted EPS of $8.50 to $8.70. Management, led by CEO Karen Lynch, expressed confidence that the interim leaders will ensure strategy execution continues without disruption. The filing does not state a timeline for Guertin's return or any change to the permanent CFO search, and it does not disclose any change to the guidance itself beyond reaffirmation. Upcoming catalysts remain on schedule, including third-quarter earnings on November 1, 2023, and Investor Day on December 5, 2023. Investors will likely focus on whether the leadership transition affects reporting cadence, the Investor Day agenda, and the timing of any permanent CFO appointment.

Oct 16, 2023 8-K

CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (Oct 13, 2023)

CVS Health (through its Aetna unit) disclosed on October 13, 2023 that CMS released the 2024 Medicare Advantage and Part D Star Ratings, and that the share of Aetna Medicare Advantage members in 4+ Star plans is expected to rise to 87% from an unmitigated 21% under the 2023 ratings. The change is driven mainly by a half-Star improvement in the Aetna National PPO (H5521), which moved from 3.5 to 4.0 Stars. Because Star Ratings determine payments two years later, this improvement affects 2025 revenue rather than 2023 or 2024 results. The company said the improvement should allow Aetna to recover the majority of the roughly $800 million to $1.0 billion mitigated 2024 revenue headwind, which had been caused by the National PPO falling from 4.5 to 3.5 Stars. Management expects to be eligible for bonus payments in 2025 but plans to reinvest a portion of the net benefit into the business. The company explicitly stated that the rating improvement is not projected to change its previously issued 2023 and 2024 guidance. Management will provide more detail on the financial impact and reinvestment plans at its Investor Day on December 5, 2023. Investors should note that the 2025 benefit is contingent on the final Star Ratings and bonus eligibility, and that the reinvestment decision will determine how much of the recovery reaches earnings.

Oct 13, 2023 8-K

Leadership Changes

CVS HEALTH Corp 8-K Report, Executive Changes (Sep 21, 2023)

CVS Health Corporation (CVS) announced a significant addition to its Board of Directors with the election of Michael F. Mahoney, effective November 1, 2023. Mr. Mahoney brings a wealth of experience from the medical device and healthcare industries, having held prominent leadership roles including President and CEO of Boston Scientific and various executive positions at Johnson & Johnson and General Electric. His appointment is expected to strengthen the board's expertise in the healthcare sector. Investors should note that Mr. Mahoney has a proven track record in driving growth and innovation within complex healthcare organizations. His prior board experience, including his recent tenure at Baxter International, suggests a familiarity with corporate governance and strategic oversight. The company has affirmed Mr. Mahoney's independence, aligning with NYSE listing standards, and his compensation will be in line with existing non-employee director practices.

Sep 21, 2023 8-K

CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (Sep 11, 2023)

CVS Health Corporation (CVS) filed an 8-K on September 11, 2023, to announce upcoming investor meetings and a webcast scheduled for September 12, 2023. During these events, senior management will reaffirm the company's previously issued full-year 2023 financial guidance. This includes maintaining the projected GAAP diluted EPS range of $6.53 to $6.75 and the Adjusted EPS range of $8.50 to $8.70. Furthermore, the company confirmed its full-year 2023 cash flow from operations guidance remains between $12.5 billion and $13.5 billion. The filing also provided a detailed reconciliation of projected GAAP diluted EPS to projected Adjusted EPS, outlining the specific non-GAAP adjustments. These include amortization of intangible assets, net realized capital losses, acquisition-related transaction and integration costs for Signify Health and Oak Street Health, restructuring charges related to streamlining the organization and terminating certain initiatives, office real estate optimization charges, and a loss on assets held for sale concerning the long-term care business. Investors should note that the Adjusted EPS is a non-GAAP measure and should be considered alongside GAAP measures, as defined by the company.

Sep 11, 2023 8-K

CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (Aug 23, 2023)

On August 23, 2023, CVS Health announced the launch of Cordavis, a wholly owned subsidiary that will work directly with manufacturers to commercialize and/or co-produce biosimilar products for the U.S. pharmaceutical market. The filing itself is a Regulation FD disclosure (Item 7.01) with the substance contained in a press release furnished as Exhibit 99.1, so it does not report new financial results, guidance changes, or quantified financial impacts on CVS's earnings or balance sheet. Cordavis's first product is Hyrimoz (adalimumab-adaz), a Humira biosimilar that CVS has contracted with Sandoz to commercialize under a Cordavis private label beginning in the first quarter of 2024. The list price will be more than 80% below Humira's current list price. Management frames the initiative as a way to expand biosimilar supply, increase competition in specialty drugs, and reduce costs for employers and consumers, citing a U.S. biosimilar market projected to grow from under $10 billion in 2022 to more than $100 billion by 2029. For investors, the key takeaway is strategic: CVS is moving upstream into biosimilar sourcing and commercialization, which could strengthen its pharmacy benefit management position and private-label offerings. However, the filing provides no revenue, margin, or capital commitment figures, so the near-term financial impact is undetermined and the initiative should be evaluated against future disclosures.

Aug 23, 2023 8-K

CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (Aug 17, 2023)

CVS Health (CVS) announced on August 17, 2023, that Blue Shield of California will diversify its pharmacy service providers starting in 2024. While CVS Caremark will no longer be the sole provider for Blue Shield of California, it will continue to offer specialty pharmacy services. The company stated that the financial impact of this partial contract termination is not expected to affect its previously issued 2023 guidance and anticipates only an immaterial impact on its longer-term outlook. This development underscores the evolving landscape of pharmacy benefit management, where specialty pharmacy spend is increasingly significant. Importantly, CVS Health reaffirmed its full-year 2023 financial guidance, including a GAAP diluted EPS range of $6.53 to $6.75, an adjusted EPS range of $8.50 to $8.70, and cash flow from operations between $12.5 billion and $13.5 billion. The company emphasized its strong market position as a leading pharmacy benefit manager, serving a broad customer base and highlighting its integrated solutions, cost leadership, and service excellence as key differentiators. Investors should monitor competitive dynamics in the PBM sector while noting the company's confidence in its ongoing performance and market strategy.

Aug 17, 2023 8-K

CVS HEALTH Corp 8-K Report, Financial Results (Aug 2, 2023)

CVS Health reported second-quarter 2023 results on August 2, 2023, with total revenues rising 10.3% year over year to $88.9 billion, driven by growth in all segments. However, profitability weakened sharply: GAAP diluted EPS fell to $1.48 from $2.29, and Adjusted EPS declined to $2.21 from $2.53. Operating income dropped 30.7% to $3.2 billion, reflecting a $496 million restructuring charge, $157 million of acquisition-related integration costs tied to Signify Health and Oak Street Health, and the absence of a $225 million prior-year gain on the PayFlex sale. Adjusted operating income fell 10.4% to $4.5 billion, with the Health Care Benefits and Pharmacy & Consumer Wellness segments the primary drags. The Health Care Benefits segment was the most significant concern. Its medical benefit ratio rose 350 basis points to 86.2%, driven by higher Medicare Advantage outpatient utilization versus pandemic-depressed prior-year levels and lower favorable prior-period reserve development. Pharmacy & Consumer Wellness adjusted operating income fell 17.4% on reimbursement pressure, lower COVID-19 vaccination and testing volumes, and a weaker cough, cold and flu season. Health Services was the bright spot, with adjusted operating income up 3.5% on improved purchasing economics. Interest expense rose 17.7% to $686 million as debt increased to fund the acquisitions. Management revised full-year 2023 GAAP diluted EPS guidance down to $6.53–$6.75 from $6.90–$7.12, reflecting the restructuring and acquisition charges, while confirming Adjusted EPS guidance of $8.50–$8.70 and operating cash flow guidance of $12.5–$13.5 billion. Year-to-date operating cash flow was strong at $13.3 billion, up from $9.0 billion. The company also flagged an Investor Day on December 5, 2023, where investors will likely seek more detail on margin recovery and the integration of recent acquisitions.

Aug 2, 2023 8-K

Leadership Changes

CVS HEALTH Corp 8-K Report, Executive Changes (Jul 20, 2023)

CVS Health Corporation (CVS) announced a significant addition to its Board of Directors with the appointment of J. Scott Kirby, effective October 1, 2023. Mr. Kirby brings extensive leadership experience, currently serving as the CEO of United Airlines Holdings, Inc. and possessing a three-decade-long career in the airline industry with prior executive roles at American Airlines and US Airways. This appointment is notable as Mr. Kirby has been deemed independent by the Board, aligning with NYSE Corporate Governance Rules and CVS Health's own guidelines. His background in operations, strategy, and executive leadership is expected to provide valuable insights to CVS Health's strategic direction and governance. While his specific committee assignments are yet to be determined, his compensation as a non-employee director will follow the company's standard practices.

Jul 20, 2023 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (Jun 2, 2023)

CVS Health Corporation (CVS) announced on June 2, 2023, the issuance and sale of a significant amount of senior notes, totaling $4.25 billion. This debt offering comprises five tranches with varying maturity dates and interest rates: $1 billion in 5.000% Senior Notes due 2029, $750 million in 5.250% Senior Notes due 2031, $1.25 billion in 5.300% Senior Notes due 2033, $1.25 billion in 5.875% Senior Notes due 2053, and $750 million in 6.000% Senior Notes due 2063. The issuance was made under the company's existing registration statement filed on May 25, 2023, and is governed by a Senior Indenture dated August 15, 2006. This move indicates a strategic capital raise by CVS Health, likely to fund operations, acquisitions, or refinance existing debt. Investors should note the weighted average interest rate and maturity profile of these new notes when assessing the company's debt structure and financial leverage.

Jun 2, 2023 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (Jun 1, 2023)

CVS Health Corporation (CVS) has announced a significant debt offering through an Underwriting Agreement dated May 30, 2023. The company intends to issue and sell a total of $5,000,000,000 in aggregate principal amount of various senior notes, with maturities ranging from 2029 to 2063 and coupon rates between 5.000% and 6.000%. This substantial capital raise, with net proceeds expected to be approximately $4,937,925,000 after expenses, is being conducted under a previously filed Registration Statement on Form S-3ASR. The closing of this transaction is anticipated on June 2, 2023, subject to standard closing conditions. Investors should note that this filing primarily concerns the debt issuance and does not provide updated financial performance figures.

Jun 1, 2023 8-K

CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (May 31, 2023)

CVS Health Corporation (CVS) has filed an 8-K report on May 31, 2023, primarily to reaffirm its previously issued full-year 2023 financial guidance. The company reiterated its GAAP diluted EPS guidance range of $6.90 to $7.12, Adjusted EPS guidance range of $8.50 to $8.70, and cash flow from operations guidance of $12.5 billion to $13.5 billion. Management also indicated that medical costs are expected to remain in line with pricing expectations and that more than 50% of full-year earnings are anticipated in the second half of 2023, with Q3 earnings expected to be modestly higher than Q4 earnings. The filing also provides a detailed reconciliation for its projected Adjusted EPS, outlining various non-GAAP adjustments. These include amortization of intangible assets, net realized capital losses, a loss on assets held for sale related to the long-term care business, acquisition-related costs for Signify Health and Oak Street Health, and office real estate optimization charges. Investors should note that these non-GAAP measures are used by the company to analyze underlying business performance and trends and are not a substitute for GAAP measures.

May 31, 2023 8-K

CVS HEALTH Corp 8-K Report, Corporate Update (May 25, 2023)

CVS Health's May 25, 2023 Form 8-K recasts parts of its 2022 Form 10-K (Items 1, 7, 7A and 8) to reflect the segment realignment made in Q1 2023 and several other changes. The company now reports four segments: Health Care Benefits, Health Services (formerly Pharmacy Services), Pharmacy & Consumer Wellness (formerly Retail/LTC), and Corporate/Other. The filing also discontinues the former Maintenance Choice segment reporting practice, excludes net realized capital gains or losses from adjusted operating income, adds Medicare Advantage star rating disclosure, and reflects the January 1, 2023 adoption of the long-duration insurance contracts accounting standard (LDTI) with a modified retrospective transition as of January 1, 2021. The 8-K is a recast of presentation and disclosure. It does not report new financial results or guidance, and it states that the information speaks as of the original February 8, 2023 10-K filing date. The most investor-relevant disclosure is the Medicare Advantage star rating impact. Based on December 31, 2022 membership, only about 21% of Medicare Advantage members are expected to be in plans rated at least 4.0 stars for 2023 ratings (used for 2024 bonus payments), down from 87% under the 2022 ratings. The main driver was a one-star decline in the Aetna National PPO, from 4.5 to 3.5 stars. That plan will no longer qualify for CMS quality bonus payments tied to 2024, though contract diversification efforts that have received regulatory approval are expected to partially mitigate the impact. This is a meaningful risk to Health Care Benefits segment margins and Medicare membership growth. For investors, the segment realignment and the change to adjusted operating income are the key items to understand when comparing historical and future segment results. The filing states that these changes, along with the other recast items, did not have a material impact on trends in results for 2021 compared with 2020. The excerpt provided is truncated before the LDTI quantitative impact is shown, so the size of that effect cannot be assessed from this document alone.

May 25, 2023 8-K

Shareholder Matters

CVS HEALTH Corp 8-K Report, Shareholder Vote Results (May 24, 2023)

This 8-K filing reports the voting results from CVS Health Corporation's (CVS) Annual Meeting of Stockholders held on May 18, 2023. The key takeaway for investors is the strong approval of management-backed proposals, including the election of all 11 director nominees and the ratification of Ernst & Young LLP as the independent auditor for 2023. Additionally, shareholders approved, on an advisory basis, the compensation of named executive officers and recommended holding future advisory votes on executive compensation annually. While the company's own proposals were overwhelmingly supported, all five stockholder proposals presented at the meeting did not receive majority approval. This indicates a general alignment between the board's recommendations and the voting outcomes for critical governance matters, suggesting stability in leadership and financial oversight. Investors can interpret these results as a sign of shareholder confidence in the current management and the company's strategic direction, at least concerning the matters presented for vote.

May 24, 2023 8-K